Bryn Mawr Trust Advisors LLC Sells 12,118 Shares of Merck & Co., Inc. $MRK

Bryn Mawr Trust Advisors LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 230,574 shares of the company’s stock after selling 12,118 shares during the period. Merck & Co., Inc. comprises 1.2% of Bryn Mawr Trust Advisors LLC’s holdings, making the stock its 16th biggest holding. Bryn Mawr Trust Advisors LLC’s holdings in Merck & Co., Inc. were worth $24,270,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chesapeake Wealth Management grew its position in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the last quarter. Westside Investment Management Inc. grew its position in Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the last quarter. Valued Wealth Advisors LLC grew its position in Merck & Co., Inc. by 26.9% in the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after acquiring an additional 94 shares during the last quarter. Payne Capital LLC grew its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock valued at $1,120,000 after acquiring an additional 97 shares during the last quarter. Finally, Abound Wealth Management grew its position in Merck & Co., Inc. by 6.8% in the fourth quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock valued at $164,000 after acquiring an additional 99 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of a number of recent analyst reports. Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research note on Friday, February 13th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Wells Fargo & Company cut their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday. They set a “neutral” rating and a $125.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Insider Activity at Merck & Co., Inc.

In other news, CMO Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the completion of the sale, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their position. The SEC filing for this sale provides additional information. 0.17% of the stock is currently owned by insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Merck & Co., Inc. Price Performance

Shares of MRK opened at $111.26 on Friday. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30. The business’s 50 day moving average price is $117.07 and its two-hundred day moving average price is $108.31. The firm has a market cap of $274.78 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the firm earned $2.22 earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 5.16 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.